Key result
The Roche digoxin 'On Line' procedure demonstrated the lowest overall interference by digoxin-like immunoreactive factor compared to Stratus and TDx methods in susceptible patient specimens.
Why the study?
Does the Roche digoxin "On Line" procedure reduce interference by digoxin-like immunoreactive factor compared to established methods in pediatric and other high-DLIF specimens?
Cross-Sectional
Does the Roche digoxin "On Line" procedure reduce interference by digoxin-like immunoreactive factor compared to established methods in pediatric and other high-DLIF specimens?
The Roche digoxin "On Line" immunoassay demonstrates low DLIF interference and requires small specimen volumes, making it highly suitable for monitoring digoxin levels in pediatric patients.
Answers are grounded in this paper and cite their sources.
May favor Roche assay to minimize DLIF interference in susceptible specimens; leaves open prospective validation before routine pediatric adoption.
We have evaluated the new Roche digoxin "On Line" procedure for use in a pediatric population with particular interest in the potential for interference by digoxin-like immunoreactive factor (DLIF). An initial study comparing digoxin values obtained with the new Roche procedure with determinations on an Abbott TDx, American Dade Stratus, and COBAS-FARA using Microgenics Cedia reagents, found good correlations with these established methods. The Roche method was suitably precise and utilized either serum or plasma. Interference by DLIF was assessed by analyzing specimens from patients not receiving digoxin but likely to contain DLIF, with the argument that non-zero values represent cross-reactivity of anti-digoxin antibodies with DLIF endogenous to these specimens. When specimens from neonates, women with second/third trimester pregnancies, and patients with renal and liver failure were assayed with the Roche, Stratus, and TDx methods, all three methods measured DLIF in some specimens, but the Roche method possessed the lowest overall DLIF interference. The modest extent of DLIF interference and the requirement of a small amount of specimen make the Roche method superior in monitoring digoxin in a pediatric population.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (1995) conducted a cross-sectional in Patients likely to contain digoxin-like immunoreactive factor (DLIF). Roche digoxin 'On Line' procedure vs. Abbott TDx, American Dade Stratus, and COBAS-FARA methods was evaluated on Interference by digoxin-like immunoreactive factor (DLIF). The Roche digoxin 'On Line' procedure demonstrated the lowest overall interference by digoxin-like immunoreactive factor compared to Stratus and TDx methods in susceptible patient specimens.
Synapse has enriched 10 related papers. Consider them for comparative context: